EquitAI LogoEquitAI
$266.11
+0.61%
ALNY

ALNY

Alnylam Pharmaceuticals, Inc.

Healthcare
Loading Chart...
FIT ANALYSIS
Required for personalization
STOCK DNA
Valuation
5/10
Quality
10/10
Growth
9/10
Strength
5/10
Dividend
1/10
Price Trend
Downwards
Momentum
Neutral
Balance Sheet
High Leverage
Earnings
Growth
Dividend Yield
0.00%
Market Cap
$35.61B
TALK TO YOUR STOCK
EQUITAI ASSISTANT

Alnylam Pharmaceuticals discovers, develops, and commercializes innovative medicines based on a breakthrough science called RNA interference. Their treatments work by silencing specific genes that cause severe genetic diseases, essentially stopping harmful protein production at the source. I have synthesized my analysis of its core fundamentals, live market action, and peer metrics to provide a comprehensive thesis. What specific areas can I detail for you?

AI can make mistakes. Verify important information.
Talk to Your Stockopen live chat
Pro EquitAI Research
Retrieving premium status...